Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 44.49 | 10.30 | 13.24 | — | 12.82 | 9.78 | 17.15 | 11.28 | 13.63 | 18.18 | 16.95 | 14.22 | 15.66 | 16.10 | 32.92 | 33.87 | 22.47 | 68.75 | 23.19 | 21.85 | 6.87 |
| — | +5.3% | -22.8% | — | -5.9% | -46.2% | +1.2% | -20.7% | -12.9% | +12.9% | -48.5% | -58.0% | -30.3% | -76.6% | +42.0% | +55.0% | +226.9% | +275.5% | -57.7% | +2.3% | -73.9% | |
| P/S Ratio | 9.67 | 4.93 | 5.27 | 4.38 | 6.33 | 4.96 | 7.63 | 5.19 | 6.42 | 7.31 | 6.69 | 5.26 | 5.93 | 5.45 | 8.12 | 10.86 | 6.59 | 10.27 | 12.01 | 14.22 | 12.88 |
| — | -0.5% | -30.9% | -15.6% | -1.4% | -32.2% | +14.0% | -1.4% | +8.3% | +34.2% | -17.6% | -51.5% | -10.1% | -46.9% | -32.4% | -23.6% | -48.8% | -16.4% | -30.9% | +11.7% | -9.9% | |
| P/B Ratio | 289.11 | 66.10 | 36.16 | 162.23 | 17.80 | 19.41 | 16.76 | 17.01 | 16.45 | 23.38 | 29.49 | 57.79 | 20.56 | 31.89 | 79.98 | 46.45 | 56.82 | 21.34 | 21.65 | 29.45 | 21.19 |
| — | +240.5% | +115.8% | +853.9% | +8.2% | -17.0% | -43.2% | -70.6% | -20.0% | -26.7% | -63.1% | +24.4% | -63.8% | +49.4% | +269.4% | +57.7% | +168.2% | -61.9% | -76.4% | -28.2% | -43.8% | |
| P/FCF | 20.96 | 10.02 | 11.26 | 9.10 | 12.78 | 16.45 | 13.18 | 8.82 | 16.36 | 31.79 | 10.41 | 12.14 | 9.89 | 17.59 | 17.42 | 24.61 | 20.08 | 39.85 | 29.77 | 17.61 | 12.30 |
| — | -39.1% | -14.6% | +3.2% | -21.9% | -48.2% | +26.6% | -27.3% | +65.4% | +80.7% | -40.2% | -50.7% | -50.7% | -55.9% | -41.5% | +39.8% | +63.2% | -13.6% | +11.6% | -44.1% | -92.2% | |
| EV / EBITDA | 17.16 | 9.97 | 11.20 | 8.83 | 10.55 | 8.87 | 14.53 | 9.67 | 11.98 | 14.68 | 14.21 | 12.78 | 14.25 | 13.23 | 22.44 | 28.05 | 15.27 | 39.80 | 20.91 | 28.61 | 20.81 |
| — | +12.4% | -22.9% | -8.7% | -11.9% | -39.6% | +2.2% | -24.4% | -15.9% | +11.0% | -36.7% | -54.4% | -6.7% | -66.8% | +7.3% | -2.0% | -26.7% | +109.5% | -34.4% | +39.2% | -15.8% | |
| EV / EBIT | 19.01 | — | 13.15 | — | 11.27 | 9.44 | 15.86 | 10.37 | 12.96 | 16.52 | 16.36 | 14.62 | 14.93 | 15.60 | 29.34 | 30.38 | 21.14 | 55.96 | 21.12 | 28.83 | 21.01 |
| — | — | -17.1% | — | -13.1% | -42.9% | -3.1% | -29.1% | -13.2% | +5.9% | -44.2% | -51.9% | -29.4% | -72.1% | +38.9% | +5.4% | +0.6% | +192.1% | -34.7% | +40.0% | -14.6% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 78.1% | 83.5% | 71.1% | 77.4% | 79.4% | 80.3% | 75.0% | 85.9% | 83.0% | 75.2% | 76.5% | 77.3% | 74.6% | 77.3% | 78.3% | 76.8% | 77.4% | 77.7% | 86.4% | 78.8% | 84.0% |
| — | +4.0% | -5.2% | -9.9% | -4.3% | +6.8% | -1.9% | +11.2% | +11.2% | -2.8% | -2.3% | +0.6% | -3.5% | -0.5% | -9.4% | -2.6% | -7.9% | -6.5% | +8.7% | +0.5% | -8.2% | |
| Operating Margin | 58.4% | 59.8% | 49.0% | 56.3% | 61.5% | 62.2% | 53.4% | 58.9% | 56.3% | 50.7% | 48.8% | 43.9% | 40.9% | 42.7% | 33.2% | 41.1% | 39.9% | 22.4% | 64.5% | 55.4% | 65.3% |
| — | -3.8% | -8.3% | -4.4% | +9.3% | +22.7% | +9.6% | +34.1% | +37.7% | +18.6% | +47.0% | +7.0% | +2.5% | +91.2% | -48.6% | -25.9% | -38.9% | -67.2% | +13.2% | -13.1% | +5.8% | |
| Net Margin | 22.7% | 47.8% | 39.8% | -31.3% | 49.5% | 50.7% | 44.6% | 46.0% | 47.2% | 40.3% | 39.2% | 37.1% | 37.9% | 33.8% | 24.4% | 31.8% | 29.5% | 14.9% | 51.3% | 65.5% | 187.0% |
| — | -5.7% | -10.7% | -168.2% | +4.7% | +25.8% | +13.7% | +23.9% | +24.7% | +19.2% | +60.5% | +16.8% | +28.4% | +127.2% | -52.3% | -51.4% | -84.2% | -77.8% | +63.6% | +8.9% | +237.3% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 153.6% | 126.6% | 111.8% | -51.2% | 41.9% | 40.5% | 27.9% | 33.6% | 36.9% | 39.9% | 58.7% | 51.3% | 40.9% | 68.9% | 33.6% | 43.3% | 31.6% | 8.2% | 26.3% | 27.9% | 107.9% |
| — | +212.4% | +300.5% | -252.7% | +13.4% | +1.5% | -52.5% | -34.6% | -9.7% | -42.1% | +74.7% | +18.6% | +29.4% | +740.9% | +27.9% | +55.0% | -70.7% | -91.6% | +3.0% | -52.3% | +204.8% | |
| ROA | 13.8% | 8.8% | 5.8% | -6.0% | 8.2% | 7.8% | 5.5% | 6.6% | 6.7% | 4.9% | 4.3% | 4.7% | 4.4% | 4.3% | 2.2% | 3.1% | 3.4% | 1.5% | 5.3% | 5.8% | 19.6% |
| — | +12.7% | +4.1% | -191.0% | +22.3% | +58.8% | +29.0% | +39.1% | +51.7% | +14.9% | +92.1% | +51.3% | +30.7% | +176.4% | -57.8% | -46.6% | -82.7% | -83.2% | +47.0% | -56.0% | +184.3% | |
| ROIC | 32.1% | 10.3% | 6.7% | 10.4% | 9.7% | 8.5% | 6.0% | 7.4% | 7.2% | 5.6% | 4.8% | 5.2% | 4.6% | 4.9% | 2.8% | 3.9% | 4.3% | 2.1% | 5.7% | 5.2% | 9.3% |
| — | +22.1% | +13.1% | +41.1% | +34.8% | +49.8% | +23.7% | +43.5% | +57.3% | +15.0% | +73.2% | +33.7% | +6.1% | +136.9% | -51.7% | -26.2% | -53.9% | -85.3% | -36.4% | -62.8% | +22.0% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 43.89 | 14.95 | 9.76 | 43.89 | 3.00 | 4.54 | 3.13 | 4.14 | 3.32 | 5.19 | 8.44 | 17.89 | 6.01 | 9.91 | 22.69 | 8.87 | 15.51 | 4.25 | 3.37 | 4.45 | 3.11 |
| — | +229.7% | +212.4% | +960.5% | -9.8% | -12.6% | -63.0% | -76.9% | -44.7% | -47.6% | -62.8% | +101.7% | -61.3% | +133.0% | +573.0% | +99.3% | +398.9% | -41.8% | -73.9% | +69.3% | -21.8% | |
| Debt / EBITDA | 2.37 | 7.46 | 9.83 | 7.62 | 6.34 | 6.77 | 9.31 | 7.69 | 8.19 | 10.92 | 12.97 | 12.32 | 13.45 | 13.00 | 20.12 | 18.45 | 13.37 | 26.76 | 11.48 | 15.30 | 11.48 |
| — | +10.2% | +5.6% | -0.8% | -22.7% | -38.0% | -28.2% | -37.6% | -39.1% | -16.0% | -35.6% | -33.3% | +0.6% | -51.4% | +75.3% | +20.6% | +16.5% | +187.1% | -32.4% | +202.0% | +19.9% | |
| Current Ratio | 4.66 | 2.71 | 2.76 | 4.66 | 1.59 | 8.36 | 8.39 | 7.80 | 10.36 | 7.41 | 6.64 | 6.64 | 7.63 | 6.58 | 6.69 | 5.65 | 5.97 | 2.72 | 8.85 | 7.91 | 8.99 |
| — | -67.6% | -67.1% | -40.3% | -84.7% | +12.9% | +26.5% | +17.6% | +35.7% | +12.6% | -0.8% | +17.4% | +27.8% | +142.2% | -24.4% | -28.5% | -33.6% | -69.0% | +1.0% | +500.6% | -51.4% | |
| Quick Ratio | 3.66 | 2.31 | 2.33 | 3.66 | 1.37 | 7.01 | 7.30 | 6.78 | 9.15 | 6.21 | 5.36 | 5.50 | 6.51 | 5.44 | 5.52 | 4.88 | 5.03 | 2.23 | 8.42 | 7.45 | 8.50 |
| — | -67.0% | -68.0% | -46.0% | -85.1% | +12.8% | +36.2% | +23.3% | +40.5% | +14.2% | -3.0% | +12.6% | +29.5% | +144.3% | -34.5% | -34.4% | -40.8% | -73.0% | +2.4% | +535.2% | -48.1% | |
| Interest Coverage | 26.76 | 51.48 | 33.74 | -19.54 | 51.97 | 47.64 | 32.79 | 40.25 | 37.50 | 27.03 | 22.31 | 20.38 | 23.59 | 21.73 | 12.50 | 16.49 | 10.81 | 10.67 | 43.02 | 27.67 | 43.09 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying HALO stock.
Halozyme Therapeutics, Inc.'s current P/E is 44.5x. The average P/E over the last 3 quarters is 12.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Halozyme Therapeutics, Inc.'s current operating margin is 58.4%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Halozyme Therapeutics, Inc.'s business trajectory between earnings reports.